Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer

Fumiyuki Shirai, Anna Mizutani, Yoko Yashiroda, Takeshi Tsumura, Yuko Kano, Yukiko Muramatsu, Tsubasa Chikada, Hitomi Yuki, Hideaki Niwa, Shin Sato,

Journal of Medicinal Chemistry · 2020 · 40 citations · 36 references

DOIFull text

Open access

Concepts

Abstract

Tankyrases (TNKS/TNKS2) belong to the poly(ADP-ribose) polymerase family. Inhibition of their enzymatic activities attenuates the Wnt/β-catenin signaling, which plays an important role in cancer pathogenesis. We previously reported the discovery of RK-287107, a spiroindoline-based, highly selective, potent tankyrase inhibitor. Herein we describe the optimization process of RK-287107 leading to RK-582, which exhibits a markedly improved robust tumor growth inhibition in a COLO-320DM mouse xenograft model when orally administered. In addition to the dose-dependent elevation and attenuation of the levels of biomarkers AXIN2 and β-catenin, respectively, results of the TCF reporter and cell proliferation studies on COLO-320DM are discussed.

References

36